Navigation Links
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
Date:4/15/2008

AMSTERDAM, April 15 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol(TM) Orphan Drug Designation for the treatment of chronic Graft versus Host Disease (GvHD). This complication of allogeneic bone marrow transplantation is highly disabilitating and can become life threatening when the patient is unresponsive to steroid treatment. Rhitol(TM) has completed a multicenter phase I/II study for patients with severe steroid resistant chronic GvHD. A phase III study is anticipated to start in 2008.

"The decision by the FDA to grant Rhitol(TM) orphan drug designation in this area of blood cancer with unmet medical need advances our efforts to develop an innovative treatment" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the United States after product approval.

About Rhitol(TM)

Rhitol(TM) is under development as a treatment for patients with chronic GvHD resistant or intolerant to immunosuppressive agents. Rhitol(TM) treatment targets activated T cells that cause GvHD and results in immune modulation within patients with chronic GvHD, restores immune tolerance and attempts to achieve disease remission.

About chronic GvHD

GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. Graft versus Host Disease is caused by immune cells from the donor graft attacking the patient's tissues and organs. Chronic GvHD usually develops some time after the transplantation and is generally treated by immunosuppressive drugs, such as ster
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...2 Reportlinker.com announces that ...atalogue: ,, Drug Discovery Technologies - A G... ,, http://www.reportlinker.com/p0164246/Drug-...-Trends--Opportunities.html ,, Drug discovery ...y pharmaceutical company,s business strategy. Ther...
(Date:12/2/2009)...2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.... ONCY ) announced today that in connection with it...ters have exercised in full their over-allotment o...ach unit is comprised of one common share and 0.4 ...t a price of US$3.00 per unit. Each whole common s...
(Date:12/2/2009)... Israel, December 2 Gamida Cell an...reclinical (animal study) safety and,efficacy of a...om Weill,Cornell Medical College and Gamida Cell. ...anemias such as Cooley,s Anemia. , Gamida...pand, ex vivo,populations of stem/progenitor cell...
(Date:12/2/2009)...PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NAS...iopharmaceutical company focused on endocrine ther...od and Drug Administration (FDA) has granted Fast ...ay inhibitor compound, perifosine (KRX-0401), for ...oma. Keryx Biopharmaceuticals, Inc. ("Keryx") ( KE...
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...herapeutics Inc., a,privately-held biopharmaceutic...vative therapies for the treatment of immune-media...$12 million in new financing from its,existing inv...ital and,Canadian Medical Discoveries Fund (CMDF).... of some of Canada,s,premier venture capital inves...
...y - Screening Ion Channels for Safety and ...LAND, Sept. 18 ChanTest will feature its expandin...drug-discovery and,development applications in boo...e in San Diego, September 24-26. ChanTest designed...e drug-discovery researchers the early,information...
...wire/--, -- The largest event for small and mediu...ess in sectors such as biotechnology, electron...products at Inno-Tech Show 2008 -- October 23...innovative technologies developed by Korean small ...: http://www.newscom.com/cgi-bin/prnh/20080917/HK...
Other Biology Technology:Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway 2ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11 2Inno-Tech Show 2008 will be held in Seoul 2
(Date:12/4/2009)...l Botanic Gardens, Kew and the Natural History Mus...s far more widespread than previously thought, wit... least part way to being "meat eaters". A review p...nd modern insights into vegetable carnivory, is pu...Journal of the Linnean Society . , Carnivorous p...
(Date:12/4/2009)... model of heart cells, University of Iowa investig...me, calmodulin kinase II (CaM kinase), disrupts th...udy, which also involved Columbia University, was ...tational Biology . , "Recently, researchers hav... as a critical regulator of the heart,s response t...
(Date:12/3/2009)... Hausen and his co-workers discovered that specifi...al cancer. Scientists soon found out how these pat...y that the main culprits are viral proteins E6 and...ontrol functions, thus promoting cell growth. , ...Z have now discovered another mechanism by which t...
Breaking Biology News(10 mins):Scientists think 'killer petunias' should join the ranks of carnivorous plants 2U-Iowa study helps advance heart-related research 2Papillomavirus silences innate immune response 2Statement by Don Spence CEO Philips Home Healthcare Solutions Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 6050 1Statement by Don Spence CEO Philips Home Healthcare Solutions Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 6050 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year to Date 2009 Financial Results 6048 1Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year to Date 2009 Financial Results 6048 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year to Date 2009 Financial Results 6048 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year to Date 2009 Financial Results 6048 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year to Date 2009 Financial Results 6048 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year to Date 2009 Financial Results 6048 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year to Date 2009 Financial Results 6048 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year to Date 2009 Financial Results 6048 8Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad Spectrum Therapeutic for 6046 1Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad Spectrum Therapeutic for 6046 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad Spectrum Therapeutic for 6046 3
...i School of Engineering professor on sabbatical in...to-build bamboo house designed to help the vast nu... earthquake. , A first batch of these houses is b...e. , Yan Xiao, an expert in structural design and...artment of Civil and Environmental Engineering, ha...
...hniques to image the complex biological systems fo...en hampered by divisions between the academic fiel...ciplinary zeal has seen a number of exciting advan...n the June issue of Physics World, Paul OShea, a b...el Somekh, an optical engineer at Nottinghams Inst...
...une 2008 issue of the Journal of the American Diet...udies you may find of interest. Below is a summary...ation or to receive a copy of a Journal article, e...Be More Like "Freshman 5" , The "Freshman 15," th... first year of college, may overstate students, ac...
Other Biology News:Bamboo instant houses will soon shelter Sichuan quake victims 2Synergy between biology and physics drives cell-imaging technology 2Highlights from the June 2008 Journal of the American Dietetic Association 2
...ovides excellent performance, reliability and flex..., including washing of ELISAs, cellular assays and...uch as for PCR clean-up. The platforms outstanding...ate washers, with options including a process cont...
...ts Laser Capture Microdissection (LCM) enables yo...uracy of molecular assays by starting with samples...ctures isolated from whole tissue or cytology samp...oped in 1996 at the National Institutes of Health ...
BioWorks 3.3 from Thermo Scientific
...screen, without Camera • The digimage sys...ion. It is computer free for compact space require... TFT color liquid crystal display is it's specific...rescent gels, colorimetric gels, auto radiography ...
Biology Products: